Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies

Set Alert for Companies

BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.

Business Strategies Deals

Novo Nordisk Broke UK Rules By ‘Disparaging’ Rival Eli Lilly

The Danish company has once again broken UK industry rules, this time by looking to get the upper hand on its GLP-1 receptor agonist market rival Eli Lilly.

Metabolic Disorders Commercial

NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach

Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.

Emerging Company Profile Cancer

Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down

What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?

Stock Watch Companies

ADAURA Survival Boost For AZ’s Tagrisso

Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.

ASCO Clinical Trials

Allogene May Have Cracked The Off-The-Shelf CAR-T Problem

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

Commercial Clinical Trials

AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?

The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.

ASCO Clinical Trials

ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.

ASCO Clinical Trials

From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.

Switzerland Companies

AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition

The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.

Gastrointestinal Immune Disorders

Plotting The Path For Pharma To Maintain New-Found Trust

Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.

Strategy Companies

ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets

Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.

China Clinical Trials
See All
UsernamePublicRestriction

Register